Temporally-modulated Pulsed Radiation Therapy (TMPRT) After Prior EBRT for Recurrent IDH-mutant Gliomas

Astrocytoma Clinical Trial

Official title:

A Pilot Study of Temporally-modulated Pulsed Radiation Therapy to Reirradiate Recurrent IDH-mutant Gliomas After Prior External Beam Radiation Therapy

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05393258
• Other study ID #: 202205105
• Status: Recruiting
• Phase: N/A
• Start date: June 28, 2022
• Est. completion date: June 28, 2027

Study information

• Verified date: April 2024
• Source: Washington University School of Medicine
• Contact: Jiayi Huang, M.D.
• Phone: 314-273-2931
• Email: jiayi.huang[@]wustl.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This clinical trial studies the side effects of temporally-modulated pulsed radiation therapy (TMPRT) in patients with IDH-mutant gliomas who have previously received radiation therapy to the brain. TMPRT is a radiation technique in which radiation is delivered in multiple small doses on a specific timed interval, instead of delivering one large dose at one time. This technique may improve efficacy while reducing toxicity and improving patient quality of life.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 12
• Est. completion date: June 28, 2027
• Est. primary completion date: June 28, 2027
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Histologically confirmed recurrent IDH-mutant gliomas (either astrocytoma or oligodendroglioma) with prior external beam radiation therapy (EBRT) to the same region. The recurrent tumor may be either histologically confirmed or based on clinical assessment. Any number of prior recurrences is allowed.
• Maxium tumor diameter of 7 cm or less.
• Prior EBRT is = 2 years ago.
• The region for reirradiation should have received at least 45 Gy from the prior EBRT but no more than 75 Gy. The prior EBRT could be either photon-based or proton-based.
• Prior SRS to the same region is permitted as long as the cumulative dose of EBRT plus SRS is no more than 75 Gy. The prior SRS should be completed at least 6 months ago.
• Life expectancy = 12 months
• At least 18 years of age.
• Karnofsky performance status (KPS) of at least 70%.
• Females of childbearing potential (defined as a female who is non-menopausal or surgically sterilized) must be willing to use an acceptable method of birth control (i.e., hormonal contraceptive, intra-uterine device, diaphragm with spermicide, condom with spermicide, or abstinence) for the duration of the study. Should a woman become pregnant or suspect she is pregnant while participating in this study, she must inform her treating physician immediately.
• Able to understand and willing to sign an IRB-approved written informed consent document (legally authorized representative permitted).

Exclusion Criteria:

• Leptomeningeal or metastatic involvement.
• Prior history of grade 3 or higher radiation necrosis that is at least possibly related to prior radiotherapy.
• Use of concurrent bevacizumab or other anti-VEGF-directed therapy during TMPRT is not allowed. If the patient is on bevacizumab, the patient needs to discontinue bevacizumab for at least 4 weeks prior to the start of TMPRT and remain stable. Other chemotherapy, immunotherapy, or target therapy can be used concurrently or adjuvantly at the discretion of treating physician.
• Medical contraindication to MRI (e.g., unsafe foreign metallic implants, incompatible pacemaker, inability to lie still for long periods, severe to end-stage kidney disease or on hemodialysis).
• Pregnant.

Related Conditions & MeSH terms

• Astrocytoma
• Glioma
• Glioma, Malignant
• Oligodendroglioma
• Oligodendroglioma, Adult

Intervention

Radiation:
• temporally-modulated pulsed radiotherapy (TMPRT)
Intensity modulated RT (IMRT) using single or two arc therapy will be used for RT delivery.

Locations

Country	Name	City	State
United States	Washington University School of Medicine	Saint Louis	Missouri

Sponsors (1)

Lead Sponsor	Collaborator
Washington University School of Medicine

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Relative changes of different subtypes of myeloid cells	Blood will be collected before the start of TMPRT and at week 6 of radiation therapy to assess for changes in myeloid cells.	At baseline and week 6 of radiation therapy.
Other	Relative changes of different subtypes of circulating T-cells	Blood will be collected before the start of TMPRT and at week 6 of radiation therapy to assess for changes in circulating T-cells.	At baseline and week 6 of radiation therapy.
Primary	Frequency of acute intolerable toxicities	Intolerable toxicities are defined as grade 3 or higher central nervous system (CNS) adverse events at least possibly related to radiation as graded by the Common Terminology Criteria for Adverse Events v5.0 with the exception of grade 3 fatigue, headache, nausea, and vomiting. Any serious adverse event leading to discontinuation of TMPRT that is at least possibly related will be considered an intolerable toxicity.	From start of treatment through 3 months
Primary	Cumulative incidence of grade 3 or higher reirradiation-related central nervous system adverse events	Adverse events are graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0	From start of treatment through 1 year
Secondary	Change in symptom burden as measured by M.D. Anderson Symptom Inventory - Brain Tumor (MDASI-BT)	The MDASI-BT consists of 23 symptom questions asking the patient to rate the severity of their symptoms in the last 24 hours. The range is an 11-point scale (0 to 10), with 0 being "not present" and 10 being "as bad as you can imagine". The symptom composite score is the average of the symptoms items, and the score ranges from 0 to 23 with a higher score indicating more severe symptoms. Symptom burden deterioration is defined as an increase of more than 1 point from baseline on the composite symptom scale.	Assessed at approximately 3 months, 6 months, and 12 months after start of treatment
Secondary	Change in interference as measured by M.D. Anderson Symptom Inventory - Brain Tumor (MDASI-BT)	The MDASI-BT consists of 6 interference questions asking the participant to rate how their symptoms interfered with how they felt and functioned in the last 24 hours. The range is an 11-point scale (0 to 10), with 0 being "did not interfere" and 10 being "interfered completely". The interference composite score is the average of the 6 items on interferences, with a higher score indicating more interference. Interference deterioration is defined as an increase of more than 1 point from the baseline on the interference score.	Assessed at approximately 3 months, 6 months, and 12 months after start of treatment
Secondary	Change in quality of life (QOL) as measured by self-reported QOL on the Linear Analog Scale Assessment (LASA)	The LASA is a single-item questionnaire that asks the participants to rate their overall quality of life. The LASA scale runs from 0 (as bad as it can be) to 10 (as good as it can be).	Assessed at approximately 3 months, 6 months, and 12 months after start of treatment
Secondary	Progression-free survival (PFS)	PFS is defined as the time from start of treatment until time of disease progression or death from any cause. Progression will be evaluated per standard clinical care based on the Response Assessment in Neuro-Oncology (RANO) criteria for low-grade glioma (van dent Bent et al., 2011).	At one year after start of treatment
Secondary	Overall survival (OS)	OS is defined as the time from start of treatment until the date of death due to any cause.	At one year after start of treatment
Secondary	Number of reirradiation adverse events		From start of treatment through month 12 follow-up

External Links

•   Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine